Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuxian He

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Advances in Experimental Medicine and Biology|October 14, 2006
Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodiesYuxian He
Current Pharmaceutical Design|October 25, 2012
Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusionYuxian He
Viral Immunology|July 23, 2005
Vaccine design for severe acute respiratory syndrome coronavirusYuxian He, Shibo Jiang
Cellular & Molecular Immunology|March 27, 2023
Cell membrane anchoring strategies for HIV gene therapyYani Gong, Yuxian He
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|September 19, 2018
[Effect of spinal cord stimulation on myocardial ischemia/infarction]Yuxian He, Liangrong Zheng
Vaccine|September 25, 2003
Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulinsYuxian He, Paul D'Agostino, Abraham Pinter
Biochemical and Biophysical Research Communications|April 18, 2006
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activityYuxian He, Jingjing Li, Shibo Jiang
Emerging Infectious Diseases|July 19, 2005
SARS vaccine developmentShibo Jiang, Yuxian He, Shuwen Liu
Antiviral Research|January 26, 2026
Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primatesYumei Zhu, Huihui Chong, Nian Liu, et al.
AIDS (London, England)|February 27, 2016
Development of potent and long-acting HIV-1 fusion inhibitorsHuihui Chong, Xiyuan Wu, Yang Su, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Advances in Experimental Medicine and Biology|October 14, 2006
Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodiesYuxian He
Current Pharmaceutical Design|October 25, 2012
Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusionYuxian He
Viral Immunology|July 23, 2005
Vaccine design for severe acute respiratory syndrome coronavirusYuxian He, Shibo Jiang
Cellular & Molecular Immunology|March 27, 2023
Cell membrane anchoring strategies for HIV gene therapyYani Gong, Yuxian He
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|September 19, 2018
[Effect of spinal cord stimulation on myocardial ischemia/infarction]Yuxian He, Liangrong Zheng
Vaccine|September 25, 2003
Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulinsYuxian He, Paul D'Agostino, Abraham Pinter
Biochemical and Biophysical Research Communications|April 18, 2006
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activityYuxian He, Jingjing Li, Shibo Jiang
Emerging Infectious Diseases|July 19, 2005
SARS vaccine developmentShibo Jiang, Yuxian He, Shuwen Liu
Antiviral Research|January 26, 2026
Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primatesYumei Zhu, Huihui Chong, Nian Liu, et al.
AIDS (London, England)|February 27, 2016
Development of potent and long-acting HIV-1 fusion inhibitorsHuihui Chong, Xiyuan Wu, Yang Su, et al.
Pageof 18